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Summary: Surveillance of drug resistance was carried out at State level to obtain data which are standardised
and comparable using guidelines prescribed by the WHO/IUATLD Working Group on Anti-tuberculosis Drug
Resistance Surveillance.
Objective: To determine the proportion of initial and acquired drug resistance in cases of pulmonary tuberculosis
in Tamilnadu, in order to use the level of drug resistance as a performance indicator of the National Tuberculosis
Programme.
Methods: Two specimens of sputum from each of a total of 713 patients attending 145 participating centres all over
the state were tested by smear and culture examination and drug susceptibility tests of Isoniazid, Rifampicin,
Ethambutol and Streptomycin.
Results: Out of 400 patients for whom drug susceptibility results were available, 384 (96%) had no history of
previous anti-tuberculosis treatment. Of these, 312 (81%) were susceptible to all the drugs tested. Resistance to
isoniazid was seen in 15.4% of patients and to Rifampicin in 4.4% including resistance to Isoniazid and Rifampicin
in 3.4%.
Conclusion: There has been a gradual increase in initial drug resistance over the years in this part of the
country.
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INTRODUCTION
The level of drug resistance is known to provide
an epidemiological indicator to assess the extent of
resistant bacterial transmission in the conmmunity as
well as success or otherwise of the National
Tuberculosis Programme (NTP). High levels of
resistance have been reported in certain regions of
the world, particularly in Asia and parts of
Africa1.7. Potential causes of drug resistance include
inadequate treatment provided by health services,
poor case-holding, poor drug supply, poor quality of
drugs, non adherence of patients to the prescribed
drug regimens and indiscriminate use of anti-
tuberculosis drugs in the private sector. However,
the most important cause of drug resistance may be
the error the health care workers in not providing
correct regimens8. High levels of Rifampicin
resistance, for instance, require adjustment of the
control programme to guarantee high cure rate.
The recommendation to use drug susceptibility
tests for monitoring and guiding tuberculosis
treatment programmes was made many years ago9.
In view of the practical difficulties in collecting
comparable data, the World Health Organization
(WHO) proposed a programme of global surveillance
of drug resistance in tuberculosis through its
collaborating centres for bacteriology of tuberculosis
which would function as Supranational Reference
Laboratories (SRL) for the respective regions 9. The
proposed programme was based on random sampling
of patients reporting to clinics for tuberculosis
treatment. Susceptibility testing was to be performed
by the reference laboratories based on a common
protocol including uniform laboratory methods. As a
first step, a regional survey was carried out in 10
Latin American countries10. The overall experience
gained in Latin America suggested that a sample
survey of drug resistance with large failure rates of
more than 5% may indicate inadequate routine
treatment and high levels of initial resistance, which
made survey of drug resistance a priority8.
Several countries in Asia and Africa undertook
national surveys in accordance with the protocol, but
regional multi-centre surveys were not completed.
Meanwhile, several countries, including Tanzania11
and South Africa 12 established systematic national
surveillance programmes. In India, there was an
urgent need to establish surveillance of drug
resistance at country level to obtain standardized and
comparable data within and among countries. In view
of the large size of the country, it was proposed to
undertake surveillance of drug resistance in one state,
Tamil Nadu to begin with, based entirely on the
guidelines of the protocol prescribed by the WHO8.
The study was conducted by the Tuberculosis
Research Centre, a WHO collaborating centre.
MATERIAL & METHODS
1. Organizational and Survey Outline
Survey area
The entire State of Tamil Nadu in south India
formed the survey area:
Central Laboratory
The Tuberculosis Research Centre (Indian
Council of Medical Research), Chennai (TRC)
was the National Central Laboratory. All
bacteriological investigations namely, smear,
culture identification and susceptibility testing
were carried out there.
Supranational Reference Laboratory (SRL)
External quality control assessment was carried
out at the Centre for Public Health Sciences,
Brisbane, Australia which validated the results
of susceptibility tests done by the Central
Laboratory (TRC). The Brisbane laboratory had
already been identified by the WHO as a
Supranational Reference Laboratory for the
region. The method of quality control, according
to internationally accepted standards, was
developed by the SRL before starting the survey.
Such a system included (a) testing at TRC of a
sample of strains sent by the SRL, and (b) re-
testing at SRL of a sample of strains tested at
TRC.
Diagnostic Centres
All the District TB Centres (DTC) at the district
headquarters and X-ray centres (XC) in taluks
of the entire state of Tamil Nadu formed the
diagnostic centres. In addition, hospitals attached
to the medical colleges in the state were also
included. In all, a total of 145 centres
participated in the study. They comprised 23
DTCs, 117 XCs and 5 medical college hospitals.
Supervision
A Central Coordinator and a team of medical
officers closely supervised all diagnostic centres
to ensure good cooperation. They promptly
identified and corrected any operational
problems. It was also verified that the procedure
for sputum smear microscopy followed at the
diagnostic centres was of an acceptable
standard 13.
Preparatory Phase
In the preparatory phase of the survey, the
Coordinator and the central laboratory jointly
assessed all the relevant indicators of the
programme, the infrastructure and procedures.
Further, the Coordinator arranged a training
programme at Chennai for the personnel
managing the District Tuberculosis Programmes.
During training, the personnel of the Central
Laboratory gave a detailed day-long explanation
of all aspects of surveillance activities such as
case selection, collection of specimens of
sputum, entries to be made in the relevant forms
and despatch of the specimens to TRC through
the postal services. The district personnel, in
turn, conducted training programmes for medical
officers and laboratory technicians at the XC’s
of their respective districts.
Data Analysis
The data analysis was done by the TRC using
the EpiInfo software.
2. Sampling
It was estimated that a sample size of at least
500 was needed for the overall survey to be able
to detect resistance level of about 30% expected
in this area with a confidence interval of 26%
to 34% and a level of confidence of 95% 14,15.
Hence, from each of the 145 diagnostic centres.
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2 specimens of sputum from 4 to 5 consecutive,
newly diagnosed smear-positive cases were
collected over a two-month period, about 700
cases in all (allowing for contamination rate of
about 5%), and sent to TRC. The diagnostic
centres also filled up a form for each specimen
giving information about previous treatment the
patient had received which was of help in
distinguishing between initial and acquired
resistance.
3.   Intake of patients
Inclusion criteria
Patients were eligible for inclusion if:
1. they had been newly registered (re-
registration of the same patient in different
centres was to be avoided);
2. they had been found to be sputum-smear
positive, at lease once during the intake
period.
3. Children under 15 years of age fulfilling the
above criteria were also eligible.
Transport of sputum specimens
Before the start of the study, the TRC supplied,
through the Coordinator, sufficient numbers of
sputum collection bottles (sterile universal
containers), each containing 5 ml of sterile 1%
cetyl pyridinium chloride solution.
At the centres, sputum specimens were collected
from patients, smears made, stained by Z-N
method and examined as per the programme
procedure. If a smear was positive, and the
patient fulfilled the other eligibility criteria, two
more specimens (5ml each) were collected from
the patient in the sputum collection bottles
containing CPC.
A total of 1375 sputum specimens was received
from 713 patients during February-March 1997.
Of these, 51 patients provided only one specimen
each while the rest gave two specimens each.
4.  Bacteriological investigations at the Central
     Laboratory
Smear examination
At TRC, smears were made from all specimens,
stained by the auramine-phenol method and
examined using fluorescence microscopy. Positive
smears were graded as 1+, 2+ and 3+ 16.
Culture
The specimens were processed by modified
petroff’s method 117, using 4% sodium hydroxide
and inoculated on to two slopes of L-J medium.
The slopes were incubated at 37o C and
examined weekly for evidence of growth till 8
weeks. The growth was graded as 1+ (20-200
cols.), 2+ (more than 100 discrete cols.) and 3+
(confluent growth). Actual  colony counts were
reported if growth was less than 20 colonies.
Identification
Culture isolates were identified as
M.tuberculosis based on niacin test, catalase at
68oC/pH 7 and growth on L-J medium with
p-nitrobenzoic acid 18,19
Susceptibility  testing
Susceptibility tests were performed for
Streptomycin by the resistance ratio (RR)
method and for Isoniazid, Rifampicin and
Ethambutol using the absolute concentration
(MIC) method on L-J medium. A 3mm loopful
of suspension of the growth, containing
approximately 4 mg/ml, was inoculated on to
after 28 days of incubation. Resistance to
Streptomycin was defined as RR of 8 or more.
An MIC of 1 mg/1 or more for Isoniazid, 128
mg/1 or more for Rifampicin and 8 mg/1 or more
for Ethambutol was interpreted as resistant 20,22.
RESULTS
Smear
On smear examination at TRC, 6.5% of the 1375
specimens were found to be smear-negative (Table
1). Duplicate smears from the same patient showed
a fair agreement with 91% concordance even in
grades (Table 2).
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Neg 90 6.5
1 + 1,054 76.7
2+ 224 16.3
3+ 7 0.5
TOTAL 1,375 100.0
Smear Grade
Total Specimens
                  No.      %
Table I.  Smear results of all specimens tested
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Neg 16 30 3 0 49 6.9
1+ 2 4 425 52 0 501 70.3
2+ 1 55 52 1 109 15.3
3+ 0 1 0 2 3 0.4
NA 0 42 8 1 51 7.2
Total No. 41 553 115 4 713
% 5.8 77.6 16.1 0.6
Smear II Smear 1
    Neg.          1+          2+         3+
Table 2. Distribution of Smear Results of duplicate
            specimens from same patient according to grade
                 of smear.
Total
No       %
Culture
A little more than half of all the specimens were
culture negative and more than half of all positive
cultures yielded 100 colonies or less.  An identical
pattern was obtained when duplicate specimens from
the same patients were examined (not tabulated). The
contamination rate was also extremely low (0.6%).
All the strains isolated were identified as
Mycobacterium tuberculosis.
Drug susceptibility test results were available
for 400 patients, including 384 patients without any
history of previous treatment and 16 patients with
previous treatment.  The pattern of resistance
observed in these patients is shown in Table 3.  Of
the 384 patients without any history of previous
treatment, the isolates from 312 (81.2%) patients
were fully susceptible to all the drugs tested, while
isolates from 72 patients had resistance to one or
more drugs.  Resistance to Isoniazid, alone or in
combination with other drugs was seen in 59 (15.4%)
patients.  Similarly, resistance to Rifampicin, alone
or with other drugs was seen in 17 (4.4%) patients.
Resistance to Isoniazid and Rifampicin together was
observed in 13 (3.4%).
Of the 16 patients with history of previous
treatment, isolates from 8 patients were fully
susceptible.  Resistance to Isoniazid, alone or with
other drugs was seen in 8 cases, Rifampicin
resistance was observed in 4 patients, all of whom
were also resistant to Isoniazid.
External Quality Control Studies
During the study period, two rounds of external
Total tested 384 100.0 16 100.0
Fully sensitive 312 81.2 8 50.0
Any resistance 72 18.8 8 50.0
Resistance to
H 29 7.6 2 12.5
R 2 0.5 0 0.00
E 2 0.5 0 0.00
S 7 1.8 0 0.00
HR 2 0.5 1 6.2
HRE 4 1.0 2 12.5
HRS 0 0.0 0 0.0
HRSE 71 8 1 6.2
HE 7 1.8 1 6.2
HS 5 1.3 0 0.00
HES 5 1.3 1 6.2
RE 0 0.0 0 0.0
RS 0 0.0 0 0.0
RES 2 0.5 0 0.0
ES 0 0.0 0 0.0
Any H Resistance 59 15.4 8 50.0
Any R Resistance 17 4.4 4 25.0
Any HR Resistance 13 3.4 4 25.0
No history of
treatment/initial
resistance
Previously
treated/acquired
resistance
No % No %
Table 3.  Summary of anti-tuberculosis drug resistance
Round I: TRC 90 100 95 100
SRL 100 90 100 100
Round II: TRC 100 100 100 100
SRL 100 100 100 100
*SRL Brisbane used BACTEC radiometric method while TRC
used conventional (RR/MIC) methods
S H R E
Table 4. Agreement in drug susceptibility results
 between TRC, Chennai and SRL, Brisbane*
Reproducibility (%)
   Retesting at
quality assurance studies were undertaken by the
Brisbane Laboratory, the results of which are
presented in Table 4.
Of the 20 cultures received from the SRL in
Round I, there was 100% agreement in the case of
Isoniazid and Ethambutol, while it was 95% for
Rifampicin and 90% with Streptomycin.  However,
in Round II, the reproducibility was 100% for all
the drugs tested.
Similarly, of the 20 strains re-tested at the SRL
in Round I, there was total agreement between
the two laboratories in the case of Streptomycin,
Rifampicin and Ethambutol. In round II, there was
100% agreement with all the four drugs tested.
DISCUSSION
The WHO / IUATLD Global Project on Anti-
tuberculosis Drug Resistance Surveillance recorded
considerable variation in the prevalence of drug
resistance among 35 countries in 5 continents. The
median prevalence of drug resistance among patients
with no history of previous treatment was 10% with
the range from 2%-40%10. Although the prevalence
of MDR-TB is generally low, there are several
countries where the situation demands immediate
intervention. Overall, the median prevalence of
primary MDR-TB was 1.4% ranging from 0-14%
10
. Among the South East Asian Region (SEAR)
countries, the prevalence of primary resistance is
readily available only for Nepal and Thailand since
they participated in the WHO supported Global
Project on Anti-tuberculosis Drug Resistance
Surveillance in 1994-1997. The median prevalence
of primary resistance to any drug was recorded as
23.2% with range of 9.8% to 36.6%. The median
prevalence of primary MDR-TB was 2.5%,
significantly higher than the global mean of 1.4%14.
However, such information for other SEAR countries,
based on standardized protocols and methods, is not
available. Although drug resistant tuberculosis has
frequently been encountered in India and its presence
has been known from the time drugs were introduced
for the treatment of tuberculosis, there is no
comprehensive report mainly due to limited facilities
available for culture and susceptibility tests across
the country. The present report on drug resistance in
the entire state of Tamil Nadu, using internationally
acceptable guidelines and a standardized methodology
gives reliable information.
Considering smear results of all specimens
tested, it was observed that 6.5% of the specimens
were negative by microscopy at this Centre. It should
be noted that one of the criteria for inclusion of
patients in this study was that they should have been
smear positive at least once during the study period.
The specimens that were sent to TRC were not
examined for smear at the diagnostic centres. Hence
this discrepancy could have been due to differences
between specimens from the same patient. Another
explanation could be that the sputum specimens got
diluted by the addition of 5 ml of CPC solution which
could have resulted in a small proportion of smears
being reported as negative. Nevertheless, the
agreement of 93.5% shows that sputum microscopy
at the diagnostic centres, with minimal infrastructure,
was up to an acceptable standard.
That a very large number of smear-positives
were culture negative in this study is of utmost
concern. This, it was realized, was due to
defective methodology provided in the study
protocol which laid down that the CPC
containing specimens should be processed by
Petroff’s method using 4% sodium hydroxide
(NaOH). This combination of CPC-NaOH was
perhaps responsible for culture negativity23.
However, by the time this was realized, the intake
was almost completed. However, towards the end of
the study, an alternative method of processing was
employed. The CPC-containing specimen was
directly centrifuged as such and the deposit was
inoculated on to two LJ slopes (direct method).
Subsequently, the deposit was re-suspended in water
to the original volume and processed by Petroff’s
method. A comparison of the results of this study on
61 specimens is shown in Table 5. It was observed
that the direct method yielded 45 positive cultures
as against only 16 by Petroff’s method, a highly
significant difference. Further, 35 out of 54 cultures
(64.8%) yielded 2+ /3+ grades as against only 4
(7.4%) by Petroff’s method.
The CPC-NaOH combination had not only
inhibited the growth of M.Tuberculosis but perhaps
also that of the contaminants, which accounted for
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Neg 6 7 3 22 38
Col. 1 0 0 7 8
1+ 2 0 0 2 4
2+/3+ 0 0 0 4 4
Total 9 7 3 35 54
Petroff ’s
method
Direct Culture
    Neg.         Col.           1+      2+/3+
Table 5.  Comparison of direct culture method with
Petroff’s method in specimens containing CPC.
Total
the very low (0.6%) contamination observed in this
study.
This observation has been repeated in a survey
conducted by us in North Arcot district (Tamil Nadu),
in 1999. A total of 635 sputum specimens from 320
patients were collected in transport medium
containing 5 ml of 1% CPC and 2% NaCI solution
and were processed directly. An interim analysis has
revealed culture positivity of 95%, negativity of 3%
and contamination of 2%. The results of this study
confirm our earlier observation once again
(unpublished data). It might be observed that the
1988-89 level of 2% MDR-TB in the North Arcot
district has gone up to about 4% in the succeeding
decade.
Considering the level of drug resistance
observed in this study, the proportion of
resistance to H, R and HR was of the order of
15.4%, 4.4% and 3.4%, respectively, in
previously untreated cases. These estimates are
similar to other surveys conducted by the TRC
in the recent past. Thus, in a study conducted in the
North Arcot district of Tamil Nadu during the
period 1985-89 on 2,779 cases, with no history of
previous anti-tuberculosis treatment or with previous
treatment of less than 2 months’ duration, initial
resistance to H was 13% and HR resistance was
1.6%14. In the district of Raichur in Karnataka State,
initial resistance to H was of the order of 13.2%24.
Data from TRC on primary resistance among 6,742
patients, from 1956 onwards for 18 different
chemotherapeutics, had shown a gradual increase in
the prevalence of primary resistance to anti-
tuberculosis drugs. For Isoniazid and Streptomycin,
the resistance rates were similar and ranged from 3-
14% with the highest level of 14% observed during
1990 for Isoniazid. Initial resistance to Rifampicin
started appearing during the 1990s and is 1.2% at
present. Resistance to HR or SHR was observed to
be less than 1% in 1990-957. However, observations
on acquired resistance in India vary in different
surveys. A retrospective analysis on a cohort of 3,357
smear-positive patients initiated on anti-tuberculosis
treatment, between April 1986 and March 1988 in
North Arcot District had shown acquired resistance
of 67% to H and 12% for R, either alone or in
combination with other anti-tuberculosis drugs25.
Elsewhere in India, an alarmingly high proportion
of acquired resistance has been reported
from the state of Gujarat26, resistance to H being 35-
60% and 3-37% for R. Other recent reports on
acquired resistance (from previously treated cases)
in centres such as Sewagram, Wardha (1982-89),
New Delhi (1990-91) and Tamil Nadu (1995)
showed a high level of resistance to Isoniazid
(20.9%, 50.7% and 23.6% respectively) and MDR-
TB (9.6%, 33.7% and 23.3% respectively) 27-28 are
not surprising considering their specialized status
where chronically ill patients with a history of
mismangement and bad treatment are referred. On
the other hand, drug resistance reported from the
Military Hospital at Pune showed a very low level
of initial resistance to H (0.6%) which could be due
to the minimal chance of indiscriminate treatment
received prior to reporting at the hospital 30.
There has perhaps been a gradual increase in
primary drug resistance in this part of India, over
the years. However, there appears to be a marginally
higher acquired resistance, which contributes tot he
problem of rise in primary drug resistance.  This could
be overcome by a strong control programme which
can reduce the creation of drug resistance in the
community such as directly observed therapy with
short course regimens (DOTS)4. Since no newer
drugs for tuberculosis are likely to become available
in the near future, the only options left for the
prevention of drug resistance are effective case-
finding, prompt and correct diagnosis and successful
treatment of patients. Apart from a strong control
programme, continuous surveillance of drug
resistance will provide information which will serve
as a useful parameter in the evaluation of control
programmes.
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Smoking Withdrawal
Syndrome
Inhaled nicotine bonds with some receptors in the body which
provide perceived pleasurable feelings. When the effect of nicotine
dissipates, the receptors send signals to the brain which are perceived
as a displeasurable feeling - the withdrawal syndrome - compelling
the smoker to light up.
The act of smoking does not, however, happen in a vacuum: It is
almost always attended with particular “settings”, situations or
emotions peculiar to each individual ‘s desires. These unfulfilled
desires make the withdrawal symptoms all the more painful. It is
mainly the psychological associations which urge a smoker to
resume smoking. Or when the nicotine level in the body is low
enough to trigger the receptors. Smokers associate cigarettes and
smoking with many aspects of their daily life. Whenever these
associations recur, there is a craving to smoke.
After stopping smoking, the physical effects of the withdrawal persist
for between 7 to 30 days. However, the craving for a cigarette
continues for months, despite the withering away of receptors after
having been deprived of nicotine. The craving persists because of
the associated settings and human emotions of the smoker.
YOU HAVE TO QUIT
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